-
Temporal effect of Afro-Caribbean race on serum pregnancy-associated plasma protein-a at 9-13 weeks' gestation in screening for aneuploidies.
Ball S, Wright D, Sodre D, Lachmann R, Nicolaides KH.
Fetal Diagn Ther 2012;31:162-9. -
First-trimester markers of aneuploidy in women positive for HIV.
Savvidou M, Samuel I, Syngelaki A, Poulton M, Nicolaides K.
BJOG 2011;118:844-8. -
Reference range of birth weight with gestation and first-trimester prediction of small-for-gestation neonates.
Poon LC, Karagiannis G, Staboulidou I, Shafiei A, Nicolaides KH.
Prenat Diagn 2011;31:58-65. -
Screening for fetal aneuploidies at 11 to 13 weeks.
Nicolaides KH.
Prenat Diagn 2011;31:7-15. -
A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment.
Nicolaides KH.
Prenat Diagn 2011;31:3-6. -
Turning the pyramid of prenatal care.
Nicolaides KH.
Fetal Diagn Ther 2011;29:183-96. -
Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11-13 weeks.
Karagiannis G, Akolekar R, Sarquis R, Wright D, Nicolaides KH.
Fetal Diagn Ther 2011;29:148-54. -
Early vaginal bleeding has no impact on markers used in first trimester aneuploidy screening.
Spencer K, Spencer CE, Stamatopoulou A, Staboulidou I, Nicolaides KH.
Prenat Diagn 2010;30:547-50. -
First trimester aneuploidy screening in the presence of a vanishing twin: implications for maternal serum markers.
Spencer K, Staboulidou I, Nicolaides KH.
Prenat Diagn 2010;30:235-40. -
Effect of temperature on the measurement of free beta-hCG and PAPP-A concentration.
Cruz JJ, Cruz G, Minekawa R, Maiz N, Nicolaides KH.
Ultrasound Obstet Gynecol 2010;36:141-6. -
First-trimester uterine artery Doppler and serum pregnancy-associated plasma protein-a in preeclampsia and chromosomal defects.
Staboulidou I, Galindo A, Maiz N, Karagiannis G, Nicolaides KH.
Fetal Diagn Ther 2009;25:336-9. -
Maternal serum screening marker levels in women with a previous aneuploidy pregnancy.
Spencer K, Staboulidou I, Cruz JJ, Karagiannis G, Nicolaides KH.
Prenat Diagn 2009;29:1242-3. -
First-trimester maternal serum matrix metalloproteinase-9 (MMP-9) and adverse pregnancy outcome.
Poon LC, Nekrasova E, Anastassopoulos P, Livanos P, Nicolaides KH.
Prenat Diagn 2009;29:553-9. -
Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation.
Kagan KO, Cicero S, Staboulidou I, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2009;33:259-64. -
Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11 + 0 to 13 + 6 weeks of gestation.
Kagan KO, Valencia C, Livanos P, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2009;33:18-22. -
The impact of fetal gender on first trimester nuchal translucency and maternal serum free beta-hCG and PAPP-A MoM in normal and trisomy 21 pregnancies.
Cowans NJ, Stamatopoulou A, Maiz N, Spencer K, Nicolaides KH.
Prenat Diagn 2009;29:578-81. -
First-trimester biochemical markers of aneuploidy and the prediction of small-for-gestational age fetuses.
Spencer K, Cowans NJ, Avgidou K, Molina F, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;31:15-9. -
Screening for adverse pregnancy outcome by ductus venosus Doppler at 11-13+6 weeks of gestation.
Maiz N, Valencia C, Emmanuel EE, Staboulidou I, Nicolaides KH.
Obstet Gynecol 2008;112:598-605. -
Screening for triploidy by the risk algorithms for trisomies 21, 18 and 13 at 11 weeks to 13 weeks and 6 days of gestation.
Kagan KO, Anderson JM, Anwandter G, Nekrasova K, Nicolaides KH.
Prenat Diagn 2008;28:1209-13. -
Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A.
Kagan KO, Wright D, Valencia C, Maiz N, Nicolaides KH.
Hum Reprod 2008;23:1968-75.